No Data
No Data
Stocks in Play: XORTX Therapeutics Inc.
XORTX Therapeutics Reprices Warrants Connected With U.S. IPO
XORTX Therapeutics (XRTX.V) on Friday said it has received TSX Venture exchange approval to reprice certain warrants. The move affects 901,000 warrants (now 101,111 after a 9:1 consolidation) that had
XORTX Therapeutics Announces Publication of Key Research in ADPKD in Peer-reviewed Journal
XORTX Therapeutics Inc. (XRTX.V and NASDAQ: XRTX), a pharmaceutical company developing therapies to treat progressive kidney disease, on Monday announced a research paper showing for the first time th
Press Release: XORTX Announces New Clinical Advisory Board Member
XORTX Announces New Clinical Advisory Board Member CALGARY, Alberta, March 27, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA
XORTX Therapeutics Provides Update
XORTX Therapeutics Inc. (XRTX), a late-stage clinical pharmaceutical company developing therapies to treat progressive kidney disease, on Tuesday provided an overview of its 2023 achievements. The com
XORTX Therapeutics Inc. Gets FDA Orphan Drug Designation For Oxypurinol For Treatment Of Autosomal Dominant Polycystic Kidney Disease
XORTX Therapeutics Inc. Gets FDA Orphan Drug Designation For Oxypurinol For Treatment Of Autosomal Dominant Polycystic Kidney Disease